Trial Profile

Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pomalidomide (Primary)
Indications Epistaxis; Hereditary haemorrhagic telangiectasia
Focus Therapeutic Use
Acronyms PATH-HHT

Most Recent Events

12 Dec 2023 Primary endpoint has been met. (Change in Epistaxis Severity Score), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
03 Nov 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com